Northeast Pharmaceutical released its 2026 half-year report. First-half operating revenue was 3.333 billion yuan, down 13.5% year on year. Net profit attributable to the parent company was 83.86 million yuan, down 35.1% year on year. Net operating cash flow was negative 73.96 million yuan, down 170.4% year on year. Second-quarter operating revenue was 1.33 billion yuan, down 30.4% year on year, and net profit attributable to the parent company was 57.23 million yuan, down 38.4% year on year. The company said the profit decline was mainly due to the pharmaceutical distribution segment's gross margin of only 5.13%, a 40.90% drop in other income such as government subsidies, and an 872% increase in financial expenses. By segment, pharmaceutical manufacturing revenue fell 20.98% year on year, while pharmaceutical distribution revenue fell 8.7% year on year.
Northeast Pharmaceutical Group Co LtdFirst-half revenue and net profit declined, operating cash flow turned negative, and financial expenses surged.
